DOI QR코드

DOI QR Code

Alpers-Huttenlocher Syndrome First Presented with Hepatic Failure: Can Liver Transplantation Be Considered as Treatment Option?

  • Park, Sowon (Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Severance Children's Hospital) ;
  • Kang, Hoon-Chul (Division of Neurology, Department of Pediatrics, Severance Children's Hospital) ;
  • Lee, Jin-Sung (Division of Clinical Genetics, Department of Pediatrics, Severance Children's Hospital) ;
  • Park, Young Nyun (Department of Pathology, Yonsei University College of Medicine) ;
  • Kim, Seung (Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Severance Children's Hospital) ;
  • Koh, Hong (Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Severance Children's Hospital)
  • Received : 2017.05.03
  • Accepted : 2017.05.26
  • Published : 2017.12.30

Abstract

Mitochondria play essential role in eukaryotic cells including in the oxidative phosphorylation and generation of adenosine triphosphate via the electron-transport chain. Therefore, defects in mitochondrial DNA (mtDNA) can result in mitochondrial dysfunction which leads to various mitochondrial disorders that may present with various neurologic and non-neurologic manifestations. Mutations in the nuclear gene polymerase gamma (POLG) are associated with mtDNA depletions, and Alpers-Huttenlocher syndrome is one of the most severe manifestations of POLG mutation characterized by the clinical triad of intractable seizures, psychomotor regression, and liver failure. The hepatic manifestation usually occurs late in the disease's course, but in some references, hepatitis was reportedly the first manifestation. Liver transplantation was considered contraindicated in Alpers-Huttenlocher syndrome due to its poor prognosis. We acknowledged a patient with the first manifestation of the disease being hepatic failure who eventually underwent liver transplantation, and whose neurological outcome improved after cocktail therapy.

Keywords

References

  1. Alpers BJ. Diffuse progressive degeneration of the gray matter of the cerebrum. Arch Neur Psych 1931;25: 469-505. https://doi.org/10.1001/archneurpsyc.1931.02230030027002
  2. Huttenlocher PR, Solitare GB, Adams G. Infantile diffuse cerebral degeneration with hepatic cirrhosis. Arch Neurol 1976;33:186-92. https://doi.org/10.1001/archneur.1976.00500030042009
  3. Harding BN. Progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher syndrome): a personal review. J Child Neurol 1990;5: 273-87. https://doi.org/10.1177/088307389000500402
  4. Naviaux RK, Nyhan WL, Barshop BA, Poulton J, Markusic D, Karpinski NC, et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome. Ann Neurol 1999; 45:54-8. https://doi.org/10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
  5. Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol 2013;48:167-78. https://doi.org/10.1016/j.pediatrneurol.2012.09.014
  6. Hynynen J, Komulainen T, Tukiainen E, Nordin A, Arola J, Kalviainen R, et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl 2014;20:1402-12. https://doi.org/10.1002/lt.23965
  7. Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 2010;51:364-73. https://doi.org/10.1016/j.ymeth.2010.05.008
  8. Avula S, Parikh S, Demarest S, Kurz J, Gropman A. Treatment of mitochondrial disorders. Curr Treat Options Neurol 2014;16:292. https://doi.org/10.1007/s11940-014-0292-7

Cited by

  1. Valproate Is Contraindicated in POLG1 Mutations vol.22, pp.1, 2017, https://doi.org/10.5223/pghn.2019.22.1.105
  2. The Perirolandic Sign: A Unique Imaging Finding Observed in Association with Polymerase γ-Related Disorders vol.41, pp.5, 2017, https://doi.org/10.3174/ajnr.a6514
  3. Clinical Attributes and Electroencephalogram Analysis of Patients With Varying Alpers’ Syndrome Genotypes vol.12, pp.None, 2017, https://doi.org/10.3389/fphar.2021.669516